Sysmex Corp is a leading healthcare company specializing in diagnostic testing equipment and technologies. The business model of Sysmex Corp revolves around the design, development, and manufacture of innovative testing systems for clinical laboratories and healthcare institutions. With a strong focus on hematological analysis and hemostasis, Sysmex Corp provides highly accurate and reliable diagnostic solutions to support disease detection, monitoring, and treatment. By leveraging advanced technologies and automation, the company enables efficient and precise diagnostic processes, ultimately contributing to better patient outcomes. Sysmex Corp's business model centers on delivering cutting-edge diagnostic solutions that empower healthcare professionals with the tools they need for accurate and timely diagnoses.

Sysmex Corp is primarily active in the healthcare and medical technology industries.

The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).

Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.

Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.

Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.

Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.

Analysts currently set an average price target of 2,391.26 JPY for the Sysmex stock (median: 2,320.50 JPY), implying +46.9 % versus the latest price. The consensus is based on 21 analyst ratings.

Sysmex Analyst Price Targets 2026

21 analysts currently rate the Sysmex stock: 16 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Sysmex to generate revenue of 516.03 B JPY and earnings per share of 79.54 JPY.

Sysmex Analyst Price Targets 2026

Converted at the current exchange rate, the Sysmex share trades at 8.77 EUR (1,628.00 JPY).

The Sysmex share (6869.T) is listed on 4 stock exchanges, including: Frankfurt (0YX.F), München (0YX.MU).

Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.

The expected revenue of Sysmex is 516.03 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sysmex is 49.60 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sysmex is currently 20.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sysmex stock.

The price-to-sales ratio (P/S) of Sysmex is currently 1.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sysmex stock.

The Eulerpool Quality Score for Sysmex is 8/10.

The ISIN of Sysmex is JP3351100007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sysmex is 897966. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sysmex is 6869.T. The ticker symbol is used to trade Sysmex shares on the stock exchange.

Over the past 12 months, Sysmex paid a dividend of 35.00 JPY . This corresponds to a dividend yield of about 2.15 %. For the coming 12 months, Sysmex is expected to pay a dividend of 64.92 JPY.

The current dividend yield of Sysmex is 2.15 %.

Sysmex pays a dividend, distributed in the months of , , , .

Sysmex paid dividends every year for the past 30 years.

For the upcoming 12 months, dividends amounting to 64.92 JPY are expected. This corresponds to a dividend yield of 3.99 %.

Sysmex is assigned to the 'Health' sector.

To receive the latest dividend of Sysmex from amounting to 18 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Sysmex distributed 28 JPY as dividends.

The dividends of Sysmex are distributed in JPY.